E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

7 clinical trials · Sponsor

Record	Firm	Date
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo (NCT07712523)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2025-11-05
Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis (NCT07712536)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2025-06-04
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. (NCT07180511)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2025-03-12
A Study of QY101 Ointment in Subjects With Plaque Psoriasis (NCT06170840)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2023-05-17
A First-in-Human Study of QY211 Gel in Adult Subjects (NCT05843422)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2023-03-01
A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis (NCT05525715)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2022-10-01
A First-in-Human Study of QY101 Ointment in Adult Subjects (NCT05429177)	E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.	2022-06-08

Every clearance here is in the API, with alerts when new ones post.